Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia

NCT00230282 is registered in ClinicalTrials.gov with Steven E. Coutre as lead sponsor.

NCT NCT00230282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00230282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Lead sponsor
Steven E. Coutre
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
October 31, 2011
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia, chronic leukemia, chronic lymphocytic leukemia (cll), leukemia